Calcineurin inhibitor sparing in paediatric solid organ transplantation: Managing the efficacy/toxicity conundrum

Drugs

Volumn 68, Issue 10, 2008, Pages 1385-1414

  Tredger, J Michael ^a   Brown, Nigel W ^a   Dhawan, Anil ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Antithymocyte globulin, therapeutic use; Basiliximab, therapeutic use; Calcineurin inhibitors, therapeutic use; Children; Everolimus, therapeutic use; Muromonab CD3, therapeutic use; Mycophenolate mofetil, therapeutic use; Sirolimus, therapeutic use

Indexed keywords

15 DEOXYSPERGUALIN; 2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ADVAGRAF; AEB 071; ALEFACEPT; ALEMTUZUMAB; ANISPERIMUS; ANTIBODY; ANTIHYPERTENSIVE AGENT; ASP 0485; ATLIZUMAB; AZASAN; AZATHIOPRINE; BASILIXIMAB; BCX 4208; BELATACEPT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CRB 15; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; EFALIZUMAB; EVEROLIMUS; FINGOLIMOD; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; ISA 247; LF 150195; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; PROTEIN KINASE C INHIBITOR; RAPAMYCIN; RECEPTOR BLOCKING AGENT; RITUXIMAB; SBR 759; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VISILIZUMAB;

ACUTE GRAFT REJECTION; AGE DISTRIBUTION; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BACTEREMIA; BACTERIAL INFECTION; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; BONE ATROPHY; CALCINEURIN INHIBITOR INDUCED NEPHROTOXICITY; CANCER RISK; CARDIAC GRAFT REJECTION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC GRAFT REJECTION; COLON CANCER; CORTICOSTEROID THERAPY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DIABETES MELLITUS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG POTENCY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; DYSLIPIDEMIA; EOSINOPHILIA; FOOD ALLERGY; GASTROINTESTINAL SYMPTOM; GENETIC MARKER; GINGIVA HYPERPLASIA; GLOMERULUS FILTRATION RATE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GRAFT DYSFUNCTION; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEARING LOSS; HEART TRANSPLANTATION; HEMOLYTIC ANEMIA; HERPES VIRUS INFECTION; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSULIN RESISTANCE; INTESTINE TRANSPLANTATION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOADING DRUG DOSE; LONG TERM CARE; LOW DRUG DOSE; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; METABOLIC SYNDROME X; MOUTH ULCER; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; PATIENT MONITORING; PEDIATRIC SURGERY; PLASMAPHERESIS; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PROTEINURIA; PSORIASIS; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SEBACEOUS GLAND TUMOR; SIDE EFFECT; SKIN CANCER; SURVIVAL; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VIRUS INFECTION; WELLBEING; WOUND HEALING IMPAIRMENT;

CALCINEURIN; CHILD; CLINICAL TRIALS AS TOPIC; CYCLOSPORINE; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; TACROLIMUS;

EID: 46249105200     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868100-00004     Document Type: Review

References (315)

1. Carrel A, Guthrie CC. Functions of a transplanted kidney. Science 1905; 22: 473-7
2. Calne R. Cyclosporine as a milestone in immunosuppression. Transplant Proc 2004; 36: 13-5S
3. Horslen S, Barr ML, Christensen LL, et al. Pediatric transplantation in the United States, 1996-2005. Am J Transplant 2007; 7: 1339-58
4. Meier-Kriesche H, Li S, Gruessner RWG, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6: 1111-31
5. Smith JM, Stablein DM, Munoz R, et al. Contributions of the Transplant Registry: the 2006 annual report of the north American pediaetric renal trials and collaborative studies (NAPRTCS). Pediatr Transplant 2007; 11: 366-73
6. Kelly DA. Current issues in pediatric transplantation. Pediatr Transplant 2006; 10: 712-20
7. Habwe VQ. Posttransplantation quality of life: more than graft function. Am J Kidney Dis 2006; 47: S98-110
8. Schwarz C, Oberbauer R. Calcineurin inhibitor sparing in renal transplantation. Curr Opin Organ Transplant 2006; 11: 632-6
9. Di Filippo S, Cochat P, Bozio A. The challenge of renal function in heart transplant children. Pediatr Nephrol 2007; 22: 333-42
10. Kearns GL, Abdel-Rhaman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action and therapy in infants and children. N Engl J Med 2003; 349: 1157-67
11. Kosti RI, Panagiotakos DB. The epidemic of obesity in children and adolescents of the world. Cent Eur J Public Health 2006; 14: 151-9
12. Lee JM. Insulin resistance in children and adolescents. Rev Endocr Metab Disord 2006; 7: 141-7
13. Kato T, Gaynor JJ, Selvaggi G, et al. Intestinal transplantation in children: a summary of clinical outcomes and prognostic factors in 108 patients from a single center. J Gastrointest Surg 2005; 9: 75-89
14. Puliyanda DP, Stablein DM, Dharnidharka VR. Younger age and antibody induction increase the risk for infection in pediatric renal transplantation: a NAPRTCS report. Am J Transplant 2007; 7: 662-6
15. Martin SR, Atkinson P, Anand R, et al. Studies of pediatric liver transplantation 2002: patient and graft survival and rejection in pediatric recipients of a first liver transplant in the United States and Canada. Pediatr Transplant 2004; 8: 273-83
16. Renoult E, Buteau C, Lamarre V, et al. Infectious risk in pediatric organ transplant recipients: is it increased with the new immunosuppressive agents? Pediatr Transplant 2005; 9: 470-9
17. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and postransplant lymphoproliferative disease in kidney recipients treated with Alemtuzumab. Am J Transplant 2007; 7: 2619-25
18. Humar A, Michaels M, Working Group ASTID. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials of recipients of organ transplantation. Am J Transplant 2006; 6: 262-74
19. Kelly D, Jara P, Rodeck B, et al. Tacrolimus and steroids versus ciclosporin microemulsion, steroids and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet 2004; 364: 1054-61
20. John U, Everding AS, Kuwertz-Broking E, et al. High prevalence of febrile urinary tract infections after pediatric renal transplantation. Nephrol Dialysis Transplant 2006; 21: 3269-74
21. Verma A, Wade JJ, Cheeseman P, et al. Risk factors for fungal infection in paediatric liver transplant recipients. Pediatr Transplant 2005; 9: 220-5
22. Shepherd RW, Turmelle Y, Nadler M, et al. Risk factors for rejection and infection in pediatric liver transplantation. Am J Transplant 2008; 8: 396-403
23. Acott PD. Polyoma virus in pediatric renal transplantation. Pediatr Transplant 2006; 10: 856-60
24. Hymes LC, Warshaw BL. Polyomavirus (BK) in pediatric renal transplants: evaluation of viremic patients with and without BK associated nephritis. Pediatr Transplant 2006; 10: 920-2
25. Pinchoff RJ, Kaufman SS, Magid MS, et al. Adenovirus infection in pediatric small bowel transplantation recipients. Transplantation 2003; 76: 183-9
26. Smith JM, McDonald RA. Emerging viral infections in transplantation. Pediatr Transplant 2006; 10: 838-43
27. Hymes LC, Warshaw BL. Sirolimus in pediatric patients: results in the first 6 months post-renal transplant. Pediatr Transplant 2005; 9: 520-2
28. Li L, Chaudhuri A, Weintraub LA, et al. Subclinical cytomegalovirus and Epstein Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 2007; 11: 187-95
29. Krantz B, Vester U, Wingen A-M, et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant 2008; 12: 474-8
30. Guthery SL, Heubi JE, Bucuvalas JC, et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003; 75: 987-93
31. Mendoza F, Kunitake H, Laks H, et al. Post-transplant lymphoproliferative disorder following pediatric heart transplantation. Pediatr Transplant 2006; 10: 60-6
32. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet 2006; 367: 233-9
33. Dharnidharka VR, Stevens G. Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation. Pediatr Transplant 2005; 9: 622-6
34. McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008; 8: 984-9
35. Herrmann BW, Sweet SC, Molter DW. Sinonasal post-transplant lymphoproliferative disorder in pediatric lung transplant patients. Otolaryngol Head Neck Surg 2005; 133: 38-41
36. Scheenstra R, Verschuuren EAM, de Haan A, et al. The value of prospective monitoring of Epstein Barr virus DNA in blood samples in pediatric liver transplants. Transplant Infect Dis 2004; 6: 15-22
37. Hurwitz M, Desai DM, Cox KL, et al. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Pediatr Transplant 2004; 8: 267-72
38. Gross TG. Post-transplant lymphoproliferative disease in children following solid organ transplant and rituximab: the final answer? Pediatr Transplant 2007; 11: 575-7
39. Comoli P, Basso S, Zecca M, et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007; 7: 1648-55
40. Tredger JM, Brown NW, Dhawan A. Immunosuppression in pediatric solid organ transplantation: opportunities, risks, and management. Pediatr Transplant 2006; 10: 879-92
41. Feng S, Buell JF, Chari RS, et al. Tumors and transplantation: the 2003 third annual ASTS state-of-the art winter symposium. Am J Transplant 2003; 3: 1481-7
42. Penn I. De novo malignancy in paediatric organ transplant recipients. J Paediatr Surgery 1994; 29: 221-8
43. Thomson MA, Suggett NR, Nightingale PG, et al. Skin surveillance of a U.K. paediatric transplant population. Br J Dermatol 2006; 156: 45-50
44. Parkekh RS, Carrol CE, Wolfe RA, et al. Cardiovascular death in children and young adults with end-stage kidney disease. J Pediatr 2002; 141: 191-7
45. Rabkin JM, Corless CL, Rosen HR, et al. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg 2002; 183: 595-9
46. Silverstein DM, Mitchell M, LeBlanc P, et al. Assessment of risk factors for cardiovascular disease in pediatric renal transplant patients. Pediatr Transplant 2007; 11: 721-9
47. Ferraris JT, Ghezzi L, Waisman G, et al. Potential cardiac risk factors in paediatric renal transplant recipients. Pediatr Nephrol 2006; 21: 119-25
48. Alvarez A, Algar FJ, Santos F, et al. Pediatric lung transplantation. Transplant Proc 2005; 37: 1519-22
49. Loo RM, Atriyarajah V, Oh C, et al. Comparison between effects of ciclosporine and tacrolimus on glomerular filtration rate in pediatric post-orthotopic liver transplant patients. Pediatr Transplant 2006; 10: 55-9
50. Yuan J, Zhou J, Chen BC, et al. Magnesium supplementation prevents chronic cyclosporine nephrotoxicity via adjusting nitric oxide synthase activity. Transplant Proc 2005; 37: 1892-5
51. Boger CA, Rummele P, Mihatsch MJ, et al. Reverse diastolic intrarenal flow due to calcineurin inhibitor (CNI) toxicity. Am J Transplant 2006; 6: 1963-7
52. Alexander SI, Fletcher JT, Nankivell B. Chronic allograft nephropathy in pediatric renal transplantation. Pediatr Nephrol 2007; 22: 17-23
53. Silverstein DM, LeBlanc P, Hempe JM, et al. Tracking of blood pressure and its impact on graft function in pediatric renal transplant patients. Pediatr Transplant 2007; 11: 860-7
54. Campbell KM, Yazigi N, Ryckman FC, et al. High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation. J Pediatr 2006; 148: 475-80
55. Alonso EM. Long-term renal function in pediatric liver and heart recipients. Pediatr Transplant 2004; 8: 381-5
56. Arora-Gupta N, Davies P, McKiernan P, et al. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation. Pediatr Transplant 2004; 8: 145-50
57. Di Filippo S. Anti-IL-2 receptor antibody vs. polyclonal antilymphocyte antibody as induction therapy in pediatric transplantation. Pediatr Transplant 2005; 9: 373-80
58. Ojo AO, Held PJ, Port FK. Chronic renal failure after transplantation of a non-renal organ. N Engl J Med 2003; 349: 931-40
59. Mention K, Lahoche-Manucci A, Bonnevalle M, et al. Renal function outcome in pediatric liver transplant recipients. Pediatr Transplant 2005; 9: 201-7
60. Kaplan B, Meier-Kriesche H-U. Death after graft loss: an im-portant late study endpoint in kidney transplantation. Am J Transplant 2002; 2: 970-4
61. Oetjen E, Baun D, Beimesche S, et al. Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice. Mol Pharmacol 2003; 63: 1289-95
62. van Hooff JP, Christiaans MHL, van Duijnhoven EM. Glucose metabolic disorder after transplantation. Am J Transplant 2007; 7: 1435-6
63. Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004; 15: 3233-9
64. Greenspan LC, Gitelman SE, Leung MA, et al. Increased incidence of post-transplant diabetes mellitus in children: a case-control analysis. Pediatr Nephrol 2004; 17: 1-5
65. Heisel O, Heisel R, Balshaw R, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004; 4: 583-95
66. Matinez-Castaelao A, Hernandez MD, Pascual J, et al. Detection and treatment of post kidney transplant hyperglycaemia: a Spanish multicentre cross-sectional study. Transplant Proc 2005; 37: 3813-6
67. Vincenti F, Friman S, Scheuermann EH, et al. Results of an international, randomized multicentre trial comparing glucose metabolism disorders and outcome with cyclosporine and tacrolimus. Am J Transplant 2007; 7: 1506-14
68. Al-Uzri A, Stablein DM, Cohn R. Postransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 2001; 72: 1020-4
69. Knoll GA, Bell RC. Tacrolimus versus ciclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999; 318: 1104-7
70. Filler G, Webb NJA, Milford DV, et al. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs cyclosporin microemulsion. Pediatr Transplant 2005; 9: 498-503
71. Lucey MR, Abdelmalek MF, Gagliardi R, et al. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant 2005; 5: 1111-9
72. Shishido S, Sato H, Asanuma H, et al. Unexpectedly high prevalence of pretransplant abnormal glucose tolerance in pediatric kidney transplant recipients. Pediatr Transplant 2006; 10: 67-73
73. Van Hooff JP, Christiaaans MHL, Van Duijnhoven EM. Tacrolimus and post-transplant diabetes mellitus in renal transplantation. Transplantation 2005; 79: 1465-9
74. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910-7
75. Filler G, Hadjiyannakis S. How to assess for impaired glucose tolerance before transplantation and should these results influence the choice of calcineurin inhibitors. Pediatr Transplant 2006; 10: 1-4
76. Schetz M, Vanhorebeek I, Wouters PJ, et al. Tight blood glucose control is renoprotective in critically ill patients. J Am Soc Nephrol 2008; 19: 571-8
77. Armstrong AK, Goldberg CS, Crowley DC, et al. Effect of age on lipid profiles in pediatric heart transplant recipients. Pediatr Transplant 2005; 9: 523-30
78. Siirtola A, Antikainen M, Ala-Houhala M, et al. Serum lipids in children 3-5 years after kidney, liver and heart transplantation. Transpl Int 2004; 17: 109-19
79. Seipelt IM, Crawford SE, Rodgers S, et al. Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin. Pediatr Transplant 2005; 23: 317-22
80. Chin C, Lukito SS, Shek J, et al. Prevention of pediatric graft coronary artery disease: atorvastatin. Pediatr Transplant 2008; 12: 442-6
81. Kobashigawa JA. Potential immunosuppressive effects of statins. Pediatr Transplant 2008; 12: 381-4
82. Mitsnefes MM. Hypertension and end-organ damage in pediatric renal transplantation. Pediatr Transplant 2004; 8: 394-9
83. Silverstein DM. Risk factors for cardiovascular disease in pediatric renal transplant recipients. Pediatr Transplant 2004; 8: 386-93
84. Mitsnefes MM, Omoloja A, McEnery PT. Short-term pediatric renal transplant survival: blood pressure and allograft function. Pediatr Transplant 2001; 5: 160-5
85. Mitsnefes MM, Khoury PR, McEnery PT. Early posttransplantation hypertension and poor long-term renal allograft survival in pediatric patients. J Pediatr 2003; 143: 98-103
86. Roche, SL, Kaufmann J, Dipchand AI, et al. Hypertension after pediatric heart transplantation is primarily associated with immunosuppressive regimen. J Heart Lung Transplant 2008; 27: 501-7
87. Erol I, Alehan F, Ozcay F, et al. Neurological complications of liver transplantation in pediatric patients: a single centre experience. Pediatr Transplant 2007; 11: 152-9
88. Saland JM. Osseous complications of pediatric transplantation. Pediatr Transplant 2004; 8: 400-15
89. Bostanci N, Ilgenli T, Pirhan DC, et al. Relationship between IL-1A polymorphisms and gingival overgrowth in renal transplant recipients receiving cyclosporin A. J Clin Periodontol 2006; 33: 771-8
90. Tumgor G, Arikan C, Kilic M, et al. Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children. Pediatr Transplant 2006; 10: 665-8
91. Hesselink DA, Van Hest RM, Mathot RAA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005; 5: 987-94
92. Ganschow R, Albani J, Grabhorn E, et al. Tacrolimus-induced cholestatic syndrome following pediatric liver transplantation and steroid-resistant graft rejection. Pediatr Transplant 2006; 10: 220-4
93. Pappas PA, Weppler D, Pinna AD, et al. Sirolimus in pediatric gastrointestinal transplantation: the use of sirolimus for pediatric transplant patients with tacrolimus-related cardiomyopathy. Pediatr Transplant 2000; 4: 45-9
94. Turska-Kmiec A, Jankowska I, Pawlowska J, et al. Reversal of tacrolimus-related hypertrophic cardiomyopathy after conversion to rapamycin in a pediatric liver transplant recipient. Pediatr Transplant 2007; 11: 319-23
95. Valentini RP, Imam A, Warrier I, et al. Sirolimus rescue for tacrolimus-associated post-transplant autoimmune hemolytic anemia. Pediatr Transplant 2006; 10: 358-61
96. Levi Z, Hazazi R, Kedar-Barnes I, et al. Switching from tacroli-mus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. Am J Transplant 2007; 7: 476-9
97. Blanchard SS, Gerrek M, Czinn S, et al. Food protein sensitivity with partial villous atrophy after pediatric liver transplantation with tacrolimus immunosuppression. Pediatr Transplant 2006; 10: 529-32
98. Granot E, Yakobovich E, Bardenstein R. Tacrolimus immunosuppression: an association with asymptomatic eosinophilia and elevated total and specific IgE levels. Pediatr Transplant 2006; 10: 690-3
99. Bucuvalas JC, O'Connor A, Buschle K, et al. Risk of hearing impairment in pediatric liver transplant recipients: a single centre study. Pediatr Transplant 2003; 7: 265-9
100. Deutsch ES, Bartling V, Lawenda B, et al. Sensorineural hearing loss in children after liver transplantation. Arch Otolaryngol Head Neck Surg 1998; 124: 529-33
101. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-29
102. Taylor AL, Watson CJE, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol/Haematol 2005; 56: 23-46
103. Dollery C. Therapeutic drugs. 2nd ed. Vol. 1. Edinburgh: Churchill Livingstone, 1999
104. Dollery C. Therapeutic drugs. 2nd ed. Vol. 2. Edinburgh: Churchill Livingstone, 1999
105. Allison AC, Eugui EM. Mechanism of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005; 80: S181-90
106. Napoli KL, Taylor PJ. From beach to bedside: history of the development of sirolimus. Ther Drug Monit 2001; 23: 559-86
107. Chapman TM, Perry CM. Everolimus. Drugs 2004; 64: 861-72
108. Kunzendorf U, Ziegler E, Kabelitz D. FTY720: the first compound of a new promising class of immunosuppressive drugs. Nephrol Dial Transplant 2004; 19: 1677-81
109. Al-Hussaini A, Tredger JM, Dhawan A. Immunosuppression in pediatric liver and intestinal transplantation: a closer look at the arsenal. J Pediatr Gastroenterol Nutr 2005; 41: 152-65
110. Krieger NR, Emre S. Novel immunosuppressants. Pediatr Transplant 2004; 8: 594-9
111. Larsen CP, Knechtle SJ, Adams A, et al. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6: 876-83
112. Silva HT, Machado PP, Felipe CR, et al. Immunotherapy for de novo renal transplantation: what's in the pipeline? Drugs Aging 2006; 66: 1665-84
113. Basu A, Tan HP, Shapiro R. Current thinking on calcineurin inhibition in kidney transplantation: 2007 [online]. Available from URL: http://cme.medscape. com/viewprogram/8075 [Accessed 2008 May 30]
114. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin-inhibitor sparing regimens in sold organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1-15
115. Roche Laboratories. CellCept package insert. Nutley (NJ), 2007 Oct
116. Rice JE, Shipp AT, Carlin JB, et al. Late reduction in cyclosporine dosage does not improve renal function in pediatric heart transplant recipients. J Heart Lung Transplant 2002; 21: 1109-12
117. Horoldt BS, Burattin M, Gunson BK, et al. Does the Banff rejection activity index predict outcome in patients with early acute cellular rejection following liver transplantation? Liver Transplant 2006; 12: 1144-51
118. Scheenstra R, Torringa MLJ, Waalkens HJ, et al. Cyclosporine A withdrawal during follow up after pediatric liver transplantation. Liver Transplant 2006; 12: 240-6
119. Tan HP, Smaldone MC, Shapiro R. Immunosuppressive preconditioning or induction regimens: evidence to date. Drugs 2006; 66: 1535-45
120. Kamel MH, Mohan P, Little DM, et al. Rabbit antithymocyte globulin as induction therapy for pediatric deceased donor kidney transplantation. J Urol 2005; 174: 703-7
121. Khositseth S, Matas AJ, Cook ME, et al. Thymoglobulin versus ATGAm induction therapy in pediatric kidney transplant recipients: a single-center report. Transplantation 2005; 79: 958-63
122. Hastings MC, Wyatt RJ, Lau KK, et al. Five year's experience with thymoglobulin induction in a pediatric renal transplant population. Pediatr Transplant 2006; 10: 805-10
123. Baron PW, Ojogho ON, Yorgin P, et al. Comparison of outcomes with low-dose anti-thymocyte globulin, basiliximab or no induction therapy in pediatric kidney transplant recipients: a retrospective study. Pediatr Transplant 2008; 12: 32-9
124. Di Filippo S, Boissonnat P, Sassolas F, et al. Rabbit antithymocyte globulin as induction immunotherapy in pediatric heart transplantation. Transplantation 2003; 75: 354-8
125. Bartosh SM, Knechtle SJ, Sollinger HW. Campath-1H use in pediatric renal transplantation. Am J Transplant 2005; 5: 1569-73
126. Benfield M, Tejani A, Harmon WE, et al. A randomised multicentre trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation. Pediatr Transplant 2005; 9: 282-92
127. Parisi F, Danesi H, Squitieri C, et al. Thymoglobuline use in pediatric heart transplantation. J Heart Lung Transplant 2003; 22: 591-3
128. Shah A, Agarwal A, Mangus R, et al. Induction immunosuppression with rabbit antithymocyte globulin in pediatric liver transplantation. Liver Transplant 2006; 12: 1210-4
129. Ellis D, Shapiro R, Moritz M, et al. Renal transplantation in children managed with lymphocyte depleting agents and low-dose maintenance tacrolimus monotherapy. Transplantation 2007; 83: 1563-70
130. Shapiro R, Ellis D, Tan HP, et al. Alemtuzumab preconditioning with tacrolimus monotherapy in pediatric renal transplantation. Am J Transplant 2007; 7: 2736-8
131. Shapiro R, Ellis D, Tan HP, et al. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Paediatrics 2006; 148: 813-8
132. Kato T, Selvaggi G, Panagiotis T, et al. Pediatric liver transplant with Campath 1H induction: preliminary report. Transplant Proc 2006; 38: 3609-11
133. Tzakis AG, Kato T, Nishida S, et al. Preliminary experience with Campath 1 (C1H) in intestinal and liver transplantation. Transplantation 2003; 75: 1227-31
134. Tejani A, Ping-Leung H, Emmett L, et al. Reduction in acute rejections decreases chronic rejection graft failure in children: a report of the North American Pediatric renal transplant Cooperative Study. Am J Transplant 2002; 2: 142-7
135. Acott PD, Lawen JG, Crocker JFS. Third dose of basiliximab in pediatric renal transplantation. Transplant Proc 2004; 36: 2628-31
136. Ortiz V, Almenar L, Martinez-Dolz L, et al. Induction therapy with daclizumab in heart transplantation: how many doses? Transplant Proc 2006; 38: 2541-2
137. Agarwal A, Pescovitz MD. Immunosuppression in pediatric solid organ transplantation. Semin Pediatr Surg 2006; 15: 142-52
138. Chapman TM, Keating GM. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 2003; 63: 2803-35
139. Smith JM, Nemeth TL, McDonald RA. Current immunosuppressive agents in pediatric renal transplantation: efficacy, side-effects and utilization. Pediatr Transplant 2004; 8: 445-53
140. Vidhun JR, Sarwal MM. Corticosteroid avoidance in pediatric renal transplantation. Pediatr Nephrol 2005; 20: 418-26
141. Oberholzer J, John E, Lumpaopong A, et al. Early discontinuation of steroids is safe and effective in pediatric kidney transplant recipients. Pediatr Transplant 2005; 9: 456-63
142. Silverstein DM, Aviles DH, LeBlanc PM, et al. Results of one year follow-up of steroid-free immunosuppression in pediatric renal transplant patients. Pediatr Transplant 2005; 9: 589-97
143. Delucchi A, Ferrario M, Varela M, et al. Pediatric renal transplantation: a single center experience. Pediatr Transplant 2006; 10: 193-7
144. Grenda R, Watson AR, Vondrak K, et al. A prospective randomized multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant 2006; 6: 1666-72
145. Gibelli NEM, Pinho-Apezzato ML, Miyatani HT, et al. Basiliximab-chimeric anti-IL2R monoclonal antibody in pediatric liver transplantation: comparative study. Transplant Proc 2004; 36: 956-7
146. Ganschow R, Grabhorn E, Schultz A, et al. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients. Pediatr Transplant 2005; 9: 741-5
147. Schuller S, Wiederkehr JC, Coelo-Lemos IM, et al. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation. Transplant Proc 2005; 37: 1151-2
148. Ogjogho O, Sahney S, Cutler D, et al. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab. Pediatr Transplant 2005; 9: 80-3
149. Spada M, Petz W, Bertani A, et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. Am J Transplant 2006; 6: 1913-21
150. Chin C, Pittson S, Luikart H, et al. Induction therapy for corticopediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation 2005; 80: 477-81
151. Duzova A, Buyan N, Bakkaloglu M, et al. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. Transplant Proc 2003; 35: 2878-80
152. Harmon WE, Meyers KE, Ingelfinger J, et al. Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation. J Am Soc Nephrol 2006; 17: 1735-45
153. Arora N, McKiernan PJ, Beaath SV, et al. Concomitant basiliximab with low dose calcineurin inhibitors in children post liver transplantation. Pediatr Transplant 2002; 6: 214-8
154. Asolati M, Heffron TG. Immunosuppression in pediatric ABO incompatible liver transplantation. Curr Opin Org Transplant 2006; 11: 621-6
155. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006; 6: 859-66
156. Vincenti F, Mendez R, Pescovitz MD, et al. A phase I/II randomized open-label multicenter trial of Efalizumab, a hu-manized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007; 7: 1770-7
157. Ettenger R, Sarwal MM. Mycophenolate mofetil in pediatric renal transplantation. Transplantation 2005; 80: S201-10
158. Kaplan B. Enteric-coated mycophenolate sodium (Myfortic): an overview of current and future use in transplantation. Drugs 2006; 66: 1-8
159. Henne T, Latta K, Strehlau J, et al. Mycophenolate mofetil induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation 2003; 76: 1326-30
160. Cransberg K, Cornelissen EAM, Davin JC, et al. Improved outcome of pediatric kidney transplantations in the Netherlands: effect of the introduction of mycophenolate mofetil. Pediatr Transplant 2005; 9: 104-11
161. Ferraris JT, Ghezzi LFR, Vallejo G, et al. Improved long-term allograft function in pediatric renal transplantation with mycophenolate mofetil. Pediatr Transplant 2005; 9: 178-82
162. Hocker B, Feneberg R, Kopf S, et al. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. Pediatr Transplant 2006; 10: 593-601
163. Jungraithmayr TC, Wiesmayr S, Staskewitz A, et al. Five-year outcome in pediatric patients with mycophenolate mofetil-based renal transplantation. Transplantation 2007; 83: 900-5
164. Groetzner J, Reichart B, Roemer U, et al. Cardiac transplantation in pediatric patients: fifteen-year experience of a single centre. Ann Thorac Surg 2005; 79: 53-61
165. Filler G, Gellermann J, Zimmering M, et al. Effect of adding mycophenolate mofetil in pediatric renal recipients with cyclosporin nephrotoxicity. Transpl Int 2000; 13: 201-6
166. David-Neto E, Araujo LMP, Sumita NM, et al. Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. Pediatr Nephrol 2003; 18: 266-72
167. Benz K, Plank C, Griebel M, et al. Mycophenolate mofetil introduction stabilizes and subsequent cyclosporine A reduction slightly improves kidney function in pediatric renal transplant patients: a retrospective analysis. Pediatr Transplant 2006; 10: 331-6
168. Plank C, Benz K, Amann K, et al. Stable graft function after reduction of calcineurin inhibitor dosage in paediatric kidney transplant recipients. Nephrol Dialysis Transplant 2006; 21: 2930-7
169. Kerecuk L, Taylor J, Clark G. Chronic allograft nephropathy and mycophenolate mofetil introduction in paediatric renal recipients. Pediatr Nephrol 2005; 20: 1630-5
170. Cransberg K, Cornelissen M, Lilien M, et al. Maintenance immunosuppression with mycophenolate mofetil and corticosteroids in pediatric kidney transplantation: temporary benefit but not without risk. Transplantation 2007; 83: 1041-7
171. Aw MM, Samaroo B, Baker AJ, et al. Calcineurin-related nephrotoxicity: reversibility in pediatric liver transplant recipients. Transplantation 2001; 72: 746-9
172. Ferraris JR, Duca P, Prigoshin N, et al. Mycophenolate mofetil and reduced doses of cyclosporine in pediatric liver transplantation with chronic renal dysfunction: changes in the immune response. Pediatr Transplant 2004; 8: 454-9
173. Evans HM, McKiernan PJ, Kelly DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation 2005; 79: 1575-80
174. Tannuri U, Gibelli NEM, Maksoud-Filho JG, et al. Mycophenolate mofetil promotes prolonged improvement of renal dysfunction after pediatric liver transplantation: experience of a single center. Pediatr Transplant 2007; 11: 82-6
175. Boyer O, Le Bidois J, Dechaux M, et al. Improvement of renal function in pediatric heart transplant recipients treated with low dose calcineurin inhibitor and mycophenolate mofetil. Transplantation 2005; 79: 1405-10
176. Brown N, Aw MM, Mieli-Vergani G, et al. Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. Ther Drug Monit 2002; 24: 598-606
177. Filler G, Foster J, Berard R, et al. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. Transplant Proc 2004; 36: 1327-31
178. Ettenger R, Bartosh S, Choi L, et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatr Transplant 2005; 9: 780-7
179. David-Neto E, Turconi A, Giron F, et al. A study about the safety and tolerability of the conversion to enteric-coated mycophenolate sodium from mycophenolate mofetil in stable pediatric renal transplant recipients [abstract no. 1517]. Am J Transplant 2004; 4: 575
180. Laskin G, Goebel J. Clinically "silent" weight loss associated with mycophenolate mofetil in pediatric renal transplant recipients. Pediatr Transplant 2008; 12: 113-6
181. Borrows R, Chusney G, Loucaidou M, et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 2006; 6: 121-8
182. Tredger JM, Brown NW, Adams JE, et al. Monitoring mycophenolate in liver transplant recipients: towards a therapeutic range. Liver Transplant 2004; 10: 492-502
183. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23: 305-15
184. Tredger JM, Brown NW. Mycophenolate: better value through monitoring? Transplantation 2006; 81: 507-8
185. Van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005; 80: S244-53
186. Buck ML. Immunosuppression with sirolimus after solid organ transplantation in children. Pediatr Pharmacother 2006; 12: 1-5
187. Dharnidharka VR. Sirolimus in pediatric solid organ transplantation. Pediatr Transplant 2005; 9: 427-9
188. Gupta P, Kaufman S, Fishbein TM. Sirolimus for solid organ transplantation in children. Pediatr Transplant 2005; 9: 269-76
189. Eisen HJ. Everolimus: a classical mammalian target of rapamycin inhibitor? Curr Opin Organ Transplant 2005; 10: 270-2
190. El-Sabrout R, Weiss R, Butt F, et al. Rejection-free protocol using sirolimus-tacrolimus combination for pediatric renal transplant recipients. Transplant Proc 2002; 34: 1942-3
191. El-Sabrout R, Weiss R, Butt F, et al. Improved lipid profile and blood sugar control in pediatric renal transplant recipients using sirolimus-tacrolimus combination. Transplant Proc 2002; 34: 1946-7
192. Vilalta R, Vila A, Nieto J, et al. Rapamycin use and rapid withdrawal of calcineurin inhibitors in pediatric renal transplantation. Transplant Proc 2003; 35: 703-4
193. Hoyer PF, Ettenger R, Kovarik JM, et al. Everolimus in pediatric de novo renal transplant patients. Transplantation 2003; 75: 2082-5
194. Nishida S, Pinna A, Verzaro R, et al. Sirolimus (rapamycin)-based rescue treatment following chronic rejection after liver transplantation. Transplant Proc 2001; 33: 1495
195. Sindhi R, Webber S, Venkataramanan R, et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 2001; 72: 851-5
196. Fishbein TM, Florman S, Gondolesi G, et al. Intestinal transplantation before and after the introduction of sirolimus. Transplantation 2002; 73: 1538-42
197. Ettenger R, Hoyer P-F, Grimm P, et al. Multicentre trial of everolimus in paediatric renal transplant recipients: results at three year. Pediatr Transplant 2008; 12: 456-63
198. Falger JC, Mueller T, Arbeiter K, et al. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant 2006; 10: 565-9
199. Ibanez JP, Monteverde ML, Goldberg J, et al. Sirolimus in pediatric renal transplantation. Transplant Proc 2005; 37: 682-4
200. Ibanez JP, Monteverde ML, Diaz MA, et al. Sirolimus in chronic allograft nephropathy in pediatric recipients. Pediatr Transplant 2007; 11: 777-80
201. Powell HR, Kara T, Jones CL. Early experience with conversion to sirolimus in a pediatric renal transplant population. Pediatr Nephrol 2007; 22: 1773-7
202. Vester U, Kranz B, Nadalin S, et al. Sirolimus rescue of renal failure in children after combined liver-kidney transplantation. Pediatr Nephrol 2005; 20: 686-9
203. Pape L, Ahlenstiel T, Ehrich JHH, et al. Reversal of loss of glomerular filtration rate in children with transplant neuropathy after switch to everolimus and low dose cyclosporine A. Pediatr Transplant 2007; 11: 291-5
204. Sindhi R, Ganjoo J, McGhee W, et al. Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants. Transplant Proc 2002; 34: 1972-3
205. Markiewicz M, Kalicinski P, Teisseyre J, et al. Rapamycin in children after liver transplantation. Transplant Proc 2003; 35: 2284-6
206. Casas-Melley AT, Falkenstein KP, Flynn LM, et al. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus. Pediatr Transplant 2004; 8: 362-6
207. Sindhi R, Seward J, Mazariegos G, et al. Replacing calcineurin inhibitors with mTOR inhibitors in children. Pediatr Transplant 2005; 9: 391-7
208. Horslen S, Torres C, Collier D, et al. Initial experience using rapamycin immunosuppression in pediatric intestinal transplant recipients. Transplant Proc 2002; 34: 934-5
209. Lobach NE, Pollock-BarZiv SM, West LJ, et al. Sirolimus immunosuppression in pediatric heart transplant recipients: a single centre experience. J Heart Lung Transplant 2005; 24: 184-9
210. Balfour IC, Srun SW, Wood EG, et al. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients. J Heart Lung Transplant 2006; 25: 518-22
211. Schachter AD, Meyers KE, Spaneas LD, et al. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Pediatr Transplant 2004; 8: 171-7
212. Wyeth Pharmaceuticals Inc. Rapamune® package insert. Philadelphia (PA): Wyeth Pharmaceuticals Inc., 2008 Mar
213. Schuberta M, Venkataramanan R, Holt DW, et al. Pharmacokinetics of sirolimus and tacrolimus in pediatric liver transplant recipients. Am J Transplant 2004; 4: 767-73
214. Schachter AD, Benfield M, Wyatt RJ, et al. Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor cotherapy. Pediatr Transplant 2006; 10: 914-9
215. Salvadori M, Budde K, Charpentier B, et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year randomized controlled trial in Europe and Australasia. Am J Transplant 2006; 6: 2912-21
216. Vanrenterghem Y, Van Hooff JP, Klinger M, et al. The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation 2004; 78: 9-14
217. Nohima M, Yoshimoto T, Nakao A, et al. Combined therapy of deoxyspergualin and plasmapheresis: a useful treatment for antibody-mediated acute rejection after kidney transplantation. Transplant Proc 2005; 37: 930-3
218. Webster A, Taylor RS, Chapman JR, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005; (4): CD003961
219. McAlister VC, Haddad E, Renouf E, et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006; 6: 1578-85
220. Neuberger JN, Gunson BK, Hubscher SG, et al. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transplant 2004; 10: 488-91
221. Pomfret EA, Fryer JP, Sima CS, et al. Liver and Intestine transplantation in the United States, 1996-2005. Am J Transplant 2007; 7: 1376-89
222. Florman S, Alloway R, Kalayoglu M, et al. Once-daily tacrolimus extended release formulation: experience at 2 years post-conversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation 2007; 83: 1639-42
223. Heffron TG, Pillen T, Smallwood GA, et al. Pediatric liver transplantation with daclizumab induction. Transplantation 2003; 75: 2040-3
224. Frauca E, Diaz MZ, de la Vega A, et al. Cyclosporine monitoring in the early post-transplant period in pediatric liver transplant recipients. Pediatr Transplant 2007; 11: 530-5
225. Iacono AT, Johnson BA, Grgurich WF, et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 2006; 354: 141-50
226. Kim JS, Aviles DH, Silverstein DM, et al. Effect of age, ethnicity and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2005; 9: 162-9
227. Montini G, Ujka F, Varagnolo C, et al. The pharmacokinetics and immunosuppressive response of tacrolimus in pediatric renal transplant recipients. Pediatr Nephrol 2006; 21: 719-24
228. Naesens M, Salvatierra O, Kambham N, et al. Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. Transplantation 2008; 85: 1139-45
229. Kausman JY, Patel B, Marks SD. Standard dosing of tacrolimus leads to overexposure in pediatric renal transplntation recipients. Pediatr Transplant 2008; 12: 329-35
230. Filler G, Rocha de Barros V, Jagger JE, et al. Cyclosporin twice or three times daily dosing in pediatric transplant patients: it is not the same! Pediatr Transplant 2006; 10: 953-6
231. Samyn M, Cheeseman P, Bevis L, et al. Cystatin C, an easy and reliable marker for assessment of renal function in children with liver disease and after liver transplantation. Liver Transplant 2005; 11: 344-9
232. Filler G, Sharma AP. How to monitor renal function in pediatric solid organ transplant receipients. Pediatr Transplant 2008; 12: 393-401
233. Christians U, Reisdorph N, Klawitter J, et al. Biomarkers of immunosuppressive drug toxicity. Curr Opin Organ Transplant 2005; 10: 284-94
234. Kurian SM, Flechner SM, Salomon DR. Genomics and proteomics in transplantation. Curr Opin Organ Transplant 2005; 10: 191-7
235. Holt DW, Johnston A. Monitoring immunosuppressive drugs: has it a future? Ther Drug Monit 2004; 26: 244-7
236. Capron A, Lerut J, Verbandert C, et al. Validation of a liquid chromatography mass spectrophotometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging for rejection. Ther Drug Monit 2007; 29: 340-8
237. Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dialysis Transplant 2003; 18: i12-5
238. Ting LSL, Villeneuve E, Ensom MHH. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit 2006; 28: 419-30
239. Citterio F. Evolution of the therapeutic drug monitoring of cyclosporine. Transplant Proc 2004; 36: 420-5S
240. Cole E, Midtvedt K, Johnston A, et al. Recommendations for the implementation of Neoral C2 monitoring in clinical practice. Transplantation 2002; 73: S19-22
241. Jorga A, Holt DW, Johnston A. Therapeutic drug monitoring of cyclosporine. Transplant Proc 2004; 36: 396-403S
242. Trompeter R, Fitzpatrick M, Hutchinson C, et al. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Pediatr Transplant 2003; 7: 282-8
243. Hmiel SP, Canter CE, Lassa-Claxton S, et al. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients. Pediatr Transplant 2007; 11: 524-9
244. Marin JG, Levine M, Ensom MHH. Is C2 monitoring or another limited sampling strategy superior to C0 monitoring in improving clinical outcomes in adult liver transplant recipients? Ther Drug Monit 2006; 28: 637-42
245. De Winter BCM, Mathot RAA, van Hest RM, et al. Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome? Exp Opin Drug Metab Toxicol 2007; 3: 251-61
246. Filler G. Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation. Pediatr Transplant 2006; 10: 707-11
247. Kuypers DRJ, Naesens M, Vermiere S, et al. The impact of uridine diphosphate glucuronyltransferase 1A9 (UGT1A9) gene promoter region single nucleotide polymorphism T-275A and C2152T on early mycophenolic acid dose interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005; 78: 351-61
248. Holt DW. Monitoring mycophenolic acid. Ann Clin Biochem 2002; 39: 173-83
249. van Gelder T, Silva HT, de Fijter H, et al. A prospective randomised study comparing fixed dose vs concentration controlled MMF regimens for de novo patients following renal transplantation (the FDCC trial) [abstract no. 819]. Am J Transplant 2006; 6: 343
250. Bloom R, Naraghi R, Cibrik DM, et al. OPTICEPT trial: interim results of 6-month efficacy and safety of monitored mycophenolate mofetil (MMF) in combination with CNI in renal transplantation [abstract no. 822]. Am J Transplant 2006; 6: 344
251. Le Meur Y, Buchler M, Theierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496-503
252. ISBA. Immunosuppressants Bayesian dose adjustments. 2008 [online]. Available from URL: https://pharmaco.chulimoges.fr/abis.htm [Accessed 2008 May 30]
253. Laroche ML, Marquet P, Vergnenegre A, et al. Mycophenolate mofetil monitoring in kidney transplant recipients: a cost effectiveness study [abstract no. 488]. Ther Drug Monit 2007; 29: 489
254. Aw MM, Brown N, Itsuka T, et al. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. Liver Transplant 2003; 9: 383-8
255. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000; 14: 100-4
256. Cattaneo D, Gaspari F, Gotti E, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002; 62: 1060-7
257. Schmidt LE, Rasmussen A, Norelykke MR, et al. The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients. Liver Transplant 2001; 7: 739-42
258. Brown NW, Pires MS, Einarsdottir EN, et al. Likely clinical advantage to monitoring mycophenolic acid by liquid chromatography tandem mass spectrometry versus immunoassay [abstract no. 163]. Ther Drug Monit 2007; 29: 511
259. Yamani MH, Starling RC, Goormastic M, et al. The impact of routine mycophenolate drug monitoring on the treatment of cardiac allograft rejection. Transplantation 2000; 69: 2326-30
260. Mourad M, Malaise J, Chaib Eddour D, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001; 47: 88-94
261. Armstrong VW, Shipkova M, Schütz E, et al. Monitoring of mycophenolic acid in pediatric renal transplant recipients. Transplant Proc 2001; 33: 1040-3
262. Willis C, Taylor PJ, Salm P, et al. Evaluation of limited sample strategies for estimation of 12 hour mycophenolic acid area under the plasma concentration: time curve in adult renal transplant recipients. Ther Drug Monit 2000; 22: 549-54
263. Budde K, Bauer S, Hambach P, et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant recipients. Am J Transplant 2007; 7: 888-98
264. Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000; 14: 97-109
265. Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit 2004; 26: 499-505
266. Kaplan B, Meier-Kriesche H, Napoli KL, et al. A limited sampling strategy for estimating sirolimus area-under-the-concentration curve. Clin Chem 1997; 43: 539-40
267. MacDonald A, Scarola J, Burke JT, et al. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22: B101-21
268. Zimmerman JJ, Ferron GM, Lim HK. The effect of a high fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol 1999; 39: 1155-61
269. Cattaneo D, Merlini S, Perico N, et al. Therapeutic drug monitoring of sirolimus; effect of concomitant immunosuppressive therapy and clinical management. Am J Transplant 2004; 4: 1345-51
270. Filler G, Womilojou T, Feber J, et al. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. Am J Transplant 2005; 5: 2005-10
271. Heffron TG, Pescovitz MD, Florman S, et al. Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. Am J Transplant 2007; 7: 1609-15
272. Op den Buijsch RAM, Van de Plas A, Stolk LML, et al. Evaluation of limited sampling strategies for tacrolimus. Eur J Clin Pharmacol 2007; 63: 1039-44
273. Halloran PF, Helms LMH, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356-61
274. Kowlalski R, Post D, Schneider MC, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17: 77-88
275. Israeli M, Klein T, Sredni B, et al. Immuknow: a new parameter in immune monitoring of pediatric liver transplantation recipients. Liver Transplant 2008; 14: 893-8
276. El-Safa EA, Fredericks S, MacPhee IAM, et al. Paradoxical responses to tacrolimus assessed by interleukin-2 gene expression. Transplant Proc 2006; 38: 3327-30
277. Martinez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7: 309-19
278. Tapirdamaz O, Pravica V, Metselaar HJ, et al. Polymorphisms in the T cell regulatory gene cytotoxic T lymphocyte antigen 4 influence the rate of acute rejection after transplantation. Gut 2006; 55: 863-8
279. Khan F, Agrawal S, Agrawal S. Genetic predisposition and renal allograft failure: implication of non-HLA genetic variants. Molec Diag Ther 2006; 10: 205-19
280. Warle MC, Metselaar HJ, Hop WCJ, et al. Cytokine gene polymorphisms and acute liver graft rejection: a meta-analysis. Liver Transplant 2005; 11: 19-26
281. Kimball P, Baker M, Fisher RA. Allograft TNFbeta and IL16 polymorphisms influence HCV recurrence and severity after liver transplantation. Liver Transplant 2006; 12: 247-52
282. Schroppel B, Murphy B. Gene variants affecting bioavailability of drugs: towards individualized immunosuppressive therapy? J Am Soc Nephrol 2003; 14: 1955-7
283. Grinyo JM, Venrenterghem Y, Nashan B, et al. Association of three polymorphisms with acute rejection after kidney transplantation: an exploratory pharmacogenetic analysis of a randomized multicenter clinical trial (the CAESAR study) [abstract no. 1020]. Am J Transplant 2006; 6: 480-1
284. Anderer G, Scharappe M, Brechlin AM, et al. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics 2000; 10: 715-26
285. Ruiz M, Gafvels M, Eggertsen G, et al. Characterization of two novel mutations in the glucocorticoid receptor gene in patients with cortisol resistance. Clin Endocrinol (Oxf) 2001; 55: 363-71
286. Cervera C, Lozano F, Saval N, et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 2007; 83: 1493-500
287. Eid AJ, Brown RA, Paya CV, et al. Association between Toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus. Transplantation 2007; 84: 511-6
288. Bouwman LH, Roos A, Terpstra OT, et al. Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology 2005; 129: 408-14
289. Laing ME, Dicker P, Moloney FJ, et al. Association of methylenetetrahydrofolate reductase polymorphism and the risk of squamous cell carcinoma in renal transplant recipients. Transplantation 2007; 84: 113-6
290. Wu L, Xu X, Shen J, et al. MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular transplantation after liver transplantation. J Surg Oncol 2007; 96: 62-8
291. Gallon L, Akalin E, Lynch P, et al. ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. Transplantation 2006; 81: 463-8
292. Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not the recipient is a major risk factor for cyclosporin-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16: 1501-11
293. Viklicky O, Hubacek JA, Kvasnicka JA, et al. Association of methylene tetrahydrofolate reductase T677 allele with early development of chronic allograft nephropathy. Clin Biochem 2004; 37: 919-24
294. Kusztal M, Radwad-Oczko M, Koscielska-Kasprzak K, et al. Possible association of CTLA-4 gene polymorphism with cyclosporine induced gingival overgrowth in kidney transplant recipients. Transplant Proc 2008; 39: 2763-5
295. Hoffmann TW, Halimi J-M, Buchler M, et al. Association between a polymorphism in the IL-12p40 gene and cytomegalovirus reactivation after kidney transplantation. Transplantation 2008; 85 (10): 1406-11
296. Marin LA, Muro M, Moya-Quiles MR, et al. Study of Fas (DC95) and FasL (CD178) polymorphisms in liver transplant recipients. Tissue Antigens 2006; 67: 117-26
297. MacPhee IAM, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and p-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486-9
298. Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 2006; 112: 184-98
299. Thervet E, Anglichaeu D, King B, et al. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76: 1233-5
300. Naesens M, Kuypers DRJ, Verbeke K, et al. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 2006; 82: 1074-84
301. Anglicheau D, Legendre C, Thervet E. Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation 2004; 78: 311-5
302. Elens L, Capron A, Van Kerckhove V, et al. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genom 2007; 17: 873-83
303. Armstrong VW, Shipkova M, van Ahsen N, et al. Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit 2004; 26: 220-6
304. Rumbo C. Azathioprine metabolite measurements: its use in current clinical practice. Pediatr Transplant 2004; 8: 606-8
305. Hesselink DA, Van Gelder T. Genetic and non-genetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther 2005; 78: 317-21
306. Kruger B, Schroppel B, Murphy BT. Genetic polymorphisms and the fate of the transplanted organ. Transplant Rev 2008; 22: 131-40
307. Cattaneo D, Perico N, Remuzzi G. From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. Am J Transplant 2004; 4: 299-310
308. Di Filippo S, Zeevi A, McDade KK, et al. Impact of TGF-B1 gene polymorphisms on late renal function in pediatric heart transplantation. Hum Immunol 2005; 66: 133-9
309. Ng FL, Holt DW, MacPhee IAM. Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. Exp Opin Pharmacother 2007; 8: 2045-58
310. Djebli N, Picard N, Rerolle J-P, et al. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comediacations on acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genom 2007; 17: 321-30
311. Heller T, Van Gelder T, Budde K, et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant 2007; 7: 1822-31
312. Fredericks EM, Lopez MJ, Magee JC, et al. Psychological functioning, nonadherence and health outcomes after pediatric liver transplantation. Am J Transplant 2007; 7: 1974-83
313. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005; 79: 466-75
314. Kahan BD, Etheridge WB. Minimization of calcineurin inhibitors: a review of de-novo strategies and conversion algorithms. Curr Opin Organ Transplant 2007; 12: 624-35
315. Mulay AV, Cockfield S, Stryker R, et al. Conversion for calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006; 82: 1153-62